(Q44534087)

3 December 2017

title

Vemurafenib and radiation therapy in melanoma brain metastases (English)

1 reference

adaptive radiation therapy

3 December 2017

main subject

0 references

Moses Tam

3

0 references

author name string

Ashwatha Narayana

1

1 reference

3 December 2017

Maya Mathew

2

1 reference

3 December 2017

Rajni Kannan

4

1 reference

3 December 2017

Kathleen M Madden

5

1 reference

3 December 2017

John G Golfinos

6

1 reference

3 December 2017

Erik C Parker

7

1 reference

3 December 2017

Patrick A Ott

8

1 reference

3 December 2017

Anna C Pavlick

9

1 reference

3 December 2017

language of work or name

1 reference

12 April 2013

1 reference

Journal of Neuro-Oncology

3 December 2017

published in

1 reference

3 December 2017

volume

113

1 reference

3 December 2017

issue

3

1 reference

3 December 2017

page(s)

411-416

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-013-1127-1

3 December 2017

exact match

0 references

cites work

Determinants of survival in patients with brain metastases from cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Determinants of outcome in melanoma patients with cerebral metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Brain metastases: current management and new developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Melanoma brain metastases and vemurafenib: need for further investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Targeted therapy in brain metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Vemurafenib for melanoma metastases to the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1127-1

Gamma knife radiosurgery for intracranial metastatic melanoma: a 6-year experience.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23579338

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-013-1127-1

1 reference

3 December 2017

1 reference